HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT (scientific article published on 17 November 2008)

NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect

Q33984778

The biology of human natural killer-cell subsets

Q34430869

IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism

Q34825943

KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation

Q35848151

A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature

Q35900982

HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A

Q36065870

Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis

Q36234414

Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis

Q36400442

Natural killer cell developmental pathways: a question of balance.

Q36427341

Positive and negative regulation of Natural Killer cells: therapeutic implications

Q36578163

Human natural killer cell development

Q36652161

GATA-3 is an important transcription factor for regulating human NKG2A gene expression

Q38330851

Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1alpha to a distinct interferon-gamma-responsive element

Q38353983

Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells

Q40241649

Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40.

Q40900792

Follow the Leader: NK Cell Receptors for Classical and Nonclassical MHC Class I

Q41732625

Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis

Q42626003

Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E.

Q42678709

Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors

Q47916179

CD94-NKG2A receptors regulate antiviral CD8(+) T cell responses

Q52014778

Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity

Q74602327

Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation

Q78744522

Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation

Q79940094

Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation

Q80805671

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

hematology

Q103824

P304

page(s)

693-699

P577

publication date

2008-11-17

P1433

published in

Bone Marrow Transplantation

Q4941523

P1476

title

HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT

P478

volume

Reverse relations

cites work (P2860)

Q51395696	A gene expression profile for non‐smoking and non‐drinking patients with head and neck cancer
Q92299151	Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Q38203261	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity
Q52312118	Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy
Q88601518	Cytomegalovirus: an unlikely ally in the fight against blood cancers?
Q41661692	Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity
Q62595290	Fully functional NK cells after unrelated cord blood transplantation
Q51320808	HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia
Q39427922	HLA-E expression and its clinical relevance in human renal cell carcinoma
Q36127663	HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma.
Q38772289	IL-27 driven upregulation of surface HLA-E expression on monocytes inhibits IFN-γ release by autologous NK cells
Q38270952	Impact of human leukocyte antigen molecules E, F, and G on the outcome of transplantation.
Q28087719	Improving natural killer cell cancer immunotherapy
Q37452181	MicroRNA-29b mediates altered innate immune development in acute leukemia
Q40247176	Mobilizing Immune Cells With Exercise for Cancer Immunotherapy.
Q90384454	NK Cells in the Treatment of Hematological Malignancies
Q37996816	Natural killer cell immune escape in acute myeloid leukemia.
Q58563701	Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells
Q36245682	Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes
Q98783374	SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway
Q38829849	Targeting natural killer cells in cancer immunotherapy
Q41684097	The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.
Q91453622	Tissue-specific tumor microenvironments influence responses to immunotherapies
Q26751011	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells
Q37957140	Use of allogeneic NK cells for cancer immunotherapy.
Q37058110	Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies